D-serine in Schizophrenia

NCT03702933 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-10-11

No results posted yet for this study

Summary

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Conditions

Interventions

DIETARY_SUPPLEMENT

D-serine

dosage

Sponsors & Collaborators

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Uriel Heresco-Levy, MD · Herzog Hospital

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2021-09-01
Completion
2021-12-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03702933 on ClinicalTrials.gov